Free Trial

Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Wellington Management Group LLP

Progyny logo with Medical background

Wellington Management Group LLP decreased its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 394,129 shares of the company's stock after selling 36,171 shares during the period. Wellington Management Group LLP owned about 0.46% of Progyny worth $6,799,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Voya Investment Management LLC lifted its position in shares of Progyny by 1.4% during the fourth quarter. Voya Investment Management LLC now owns 51,792 shares of the company's stock worth $893,000 after purchasing an additional 701 shares in the last quarter. Signaturefd LLC lifted its holdings in Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after buying an additional 1,355 shares in the last quarter. KBC Group NV boosted its position in Progyny by 84.6% in the 4th quarter. KBC Group NV now owns 4,669 shares of the company's stock valued at $81,000 after buying an additional 2,140 shares during the period. F M Investments LLC grew its stake in shares of Progyny by 13.0% in the fourth quarter. F M Investments LLC now owns 20,420 shares of the company's stock worth $352,000 after acquiring an additional 2,342 shares in the last quarter. Finally, Entropy Technologies LP increased its position in shares of Progyny by 5.5% during the fourth quarter. Entropy Technologies LP now owns 47,883 shares of the company's stock worth $826,000 after acquiring an additional 2,499 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PGNY has been the subject of several analyst reports. Canaccord Genuity Group lowered their target price on Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Bank of America upped their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Finally, BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target for the company in a research note on Monday, March 31st. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, Progyny presently has an average rating of "Hold" and an average price target of $23.45.

View Our Latest Report on Progyny

Progyny Stock Up 0.3%

PGNY traded up $0.06 on Thursday, reaching $21.36. The company had a trading volume of 604,661 shares, compared to its average volume of 1,702,583. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $30.42. The stock has a market capitalization of $1.83 billion, a PE ratio of 36.83, a P/E/G ratio of 2.39 and a beta of 1.37. The stock has a 50-day moving average price of $22.07 and a 200-day moving average price of $20.24.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.28). The firm had revenue of $324.04 million during the quarter, compared to analysts' expectations of $307.86 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm's revenue for the quarter was up 16.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.17 earnings per share. As a group, analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

About Progyny

(Free Report)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Stories

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Should You Invest $1,000 in Progyny Right Now?

Before you consider Progyny, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.

While Progyny currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Dirt-Cheap Stocks in a Market That’s Getting Expensive
Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines